

Thrombotics and Antithrombotics

David E. Slattery

Charles V. Pollack, Jr

REFERENCES

1. Ageno W, Gallus AS, Wittkowsky A, et al: Oral anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl.): e44S, 2012. [PMID: 22315269]
2. Holbrook A, Schulman S, Witt DM, et al: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (Suppl): e152S, 2012. [PMID: 22315259]
3. De Santo LS, Romano G, Della Corta A, et al: Mechanical aortic valve replacement in young women planning on pregnancy. Maternal and fetal outcomes under low oral anticoagulation, a pilot observational study on a comprehensive pre-operative counseling protocol. *J Am Coll Cardiol* 58: 1110, 2012. [PMID: 22421305]
4. Spyropoulos AC: Bridging therapy and oral anticoagulation: current and future prospects. *Curr Opin Hematol* 17: 444, 2010. [PMID: 20613508]
5. Kaatz S, Paje D: Update in bridging anticoagulation. *J Thromb Thrombolysis* 31: 259, 2011. [PMID: 21327504]
6. Douketis JD, Spyropoulos AC, Spencer FA, et al: Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physician Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl): e326S, 2012. [PMID: 22315266]
7. Crowther MA, Ageno W, Garcia D, et al: Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. *Ann Intern Med* 150: 293, 2009. [PMID: 19258557]
8. Tomaselli GF, Mahaffey KW, Cuker A, et al: 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulation. *J Am Coll Cardiol* 70: 3042, 2017. [PMID: 29203195]
9. Denas G, Marzot F, Offelli P, et al: Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. *J Thromb Thrombolysis* 27: 340, 2009. [PMID: 18338109]
10. Grobler C, Callum J, McCluskey SA: Reversal of vitamin K antagonists prior to urgent surgery. *Can J Anaesth* 57: 458, 2010. [PMID: 20077167]
11. Vang ML, Hvas AM, Ravn HB: Urgent reversal of vitamin K antagonist therapy. *Acta Anaesthesiol Scand* 55: 507, 2011. [PMID: 21418150]
12. Rolfe S, Papadopoulos S, Cabral KP: Controversies of anticoagulation reversal in life-threatening bleeds. *J Pharm Pract* 23: 217, 2010. [PMID: 21507817]
13. Britt RB, Brown JN: Characterizing the severe reactions of parenteral vitamin K1. *Clin Appl Thromb Hemost* 24: 5, 2018. [PMID: 28301903]
14. Bhagirath VC, O'Malley L, Crowther MA: Management of bleeding complications in the anticoagulated patient. *Semin Hematol* 48: 285, 2011. [PMID: 22000094]
15. Bershad EM, Suarez JI: Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. *Neurocrit Care* 12: 403, 2010. [PMID: 19967567]
16. Bechtel B, Nunez T, Lyon J, et al: Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review. *Int J Emerg Med* 4: 40, 2011. [PMID: 21740550]
17. Morris TA: New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors. *Clin Chest Med* 31: 707, 2010. [PMID: 21047577]
18. Bovio JA, Smith SM, Gums JG: Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease. *Ann Pharmacother* 45: 603, 2011. [PMID: 21540406]
19. Lee CJ, Ansell JE: Direct thrombin inhibitors. *Br J Clin Pharmacol* 72: 581, 2011. [PMID: 21241354]
20. Montoya RC, Gajra A: Current status of new anticoagulants in the management of venous thromboembolism. *Adv Hematol* 2012: 856341, 2012. [PMID: 22496694]
21. Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW: Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. *J Med Toxicol* 7: 281, 2011. [PMID: 21887485]
22. Pollack CV, Reilly PA, Van Ryn J, et al: Idarucizumab for dabigatran reversal —full cohort analysis. *N Engl J Med* 377: 431, 2017. [PMID: 28693366]
23. Cuker A, Burnett A, Triller D, et al: Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. *Am J Hematol* 2019 Mar 27 [Epub ahead of print] [PMID: 30916798]
24. Levi M, Eerenberg E, Kamphuisen PW: Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. *J Thromb Haemost* 9: 1705, 2011. [PMID: 21729240]
25. Toschi V, Lettino M: Inhibitors of propagation of coagulation: factors V and X. *Br J Clin Pharmacol* 72: 563, 2011. [PMID: 21545479]
26. Lee K, Cham S, Lam S: Betrixaban: a novel factor Xa inhibitor for the prevention of venous thromboembolism in acutely ill medical patients. *Cardiol Rev* 26: 331, 2018. [PMID: 30067518]
27. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA: Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. *Chest* 151: 127, 2017. [PMID: 27637548]
28. Weitz JI, Eikelboom JW, Samama MM: New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl): e120S, 2012. [PMID: 22315258]
29. Connolly SJ, Milling TJ, Eikelboom JW, et al: Andexanet alfa for acute major bleeding associated with factor Xa inhibitors *N Engl J Med* 375: 1131, 2016. [PMID: 27573206]
30. Garcia DA, Baglin TP, Weitz JI, Samama MM: Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl): e24S, 2012. [PMID: 22315264]
31. Whitman-Purves E, Coons JC, Miller T, et al: Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms. *Clin Appl Thromb Hemost* 24: 310, 2018. [PMID: 29212374]
32. Witt DM, Nieuwlaar R, Clark NP, et al: American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Adv* 2: 3257, 2018. [PMID: 30482765]
33. Babin JL, Traylor KL, Witt DM: Laboratory monitoring of low-molecular-weight heparin and fondaparinux. *Semin Thromb Hemost* 43: 261, 2017. [PMID: 27281281]
34. Wei MY, Ward SM: The anti-factor Xa range for low molecular weight heparin thromboprophylaxis. *Hematol Rep* 7: 5844, 2015. [PMID: 26733269]
35. Alban S: Adverse effects of heparin. *Handb Exp Pharmacol* 207: 211, 2012. [PMID: 22566227]
36. Linkins LA, Dans AL, Moores LK, et al: Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl): e495S, 2012. [PMID: 22315270]
37. Warkentin TE: Agents for the treatment of heparin-induced thrombocytopenia. *Hematol Oncol Clin North Am* 24: 755, 2010. [PMID: 20659659]
38. Vatanparast R, Lantz S, Ward K, et al: Evaluation of a pretest scoring system (4Ts) for the diagnosis of heparin-induced thrombocytopenia in a university hospital setting. *Postgrad Med* 124: 36, 2012. [PMID: 23322137]
39. Cuker A, Arepally GM, Chong BH, et al: American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. *Blood Adv* 2: 3360, 2018. [PMID: 30482768]
40. Mastroiacovo D, Sala G, Dentali F: The safety of fondaparinux sodium for the treatment of venous thromboembolism. *Expert Opin Drug Saf* 15: 1259, 2016. [PMID: 27537418]
41. Elmer J, Wittels KA: Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature. *Transfus Med* 22: 108, 2012. [PMID: 22171588]
42. Nagler M, Haslauer M, Wuillemin K: Fondaparinux: data on efficacy and safety in special situations. *Thromb Res* 129: 407, 2012. [PMID: 22133273]
43. Van De Car DA, Rao SV, Ohman EM: Bivalirudin: a review of the pharmacology and clinical application. *Expert Rev Cardiovasc Ther* 8: 1673, 2010. [PMID: 21108549]
44. Nührenberg TG, Hochholzer W, Mashayekhi K, Ferenc M, Neumann FJ: Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials. *Clin Res Cardiol* 107: 807, 2018. [PMID: 29654437]
45. Warner TD, Nylander S, Whitting C: Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. *Br J Clin Pharmacol* 72: 619, 2011. [PMID: 21320154]
46. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI: Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl): e89S, 2012. [PMID: 22315278]
47. Tantry US, Gurbel PA: Current options in oral antiplatelet strategies during percutaneous coronary interventions. *Rev Cardiovasc Med* 12 (Suppl 1): S4, 2011. [PMID: 22080986]
48. Menozzi A, Lina D, Conte G, Mantovani F, Ardisino D: Antiplatelet therapy in acute coronary syndromes. *Expert Opin Pharmacother* 13: 27, 2012. [PMID: 22149366]
49. Arnett DK, Blumenthal RS, Albert MA, et al: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019 Mar 17. [Epub ahead of print] [PMID: 30879355]
50. Murphy S, McCarthy CP, McEvoy JW: Aspirin for the Primary Prevention of Cardiovascular Disease: Weighing Up the Evidence. *Am J Med* 2019 Mar 12. [Epub ahead of print] [PMID: 30871925]
51. Gibson CM, Pride YB, Aylward PE, et al: Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. *J Thromb Thrombolysis* 27: 11, 2009. [PMID: 18695943]
52. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al: Duration of treatment and nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. *Circulation* 123: 2226, 2011. [PMID: 21555710]
53. Amsterdam EA, Wender NK, Brindis RG, et al: 2014 AHA/ACC guideline for the management of patients with non-ST-segment elevation acute coronary syndromes. *J Am Coll Cardiol* 64: e139, 2014. [PMID: 25260718]
54. O'Gara PT, Kushner FG, Ascheim DD, et al: 2013 ACCF/AHA guideline for the management of ST-segment-elevation myocardial infarction. *J Am Coll Cardiol* 61: e78, 2013. [PMID: 23256914]
55. Kushner FG, Hand M, Smith SC Jr, et al: 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 120: 2271, 2009. [PMID: 19942100]

56. Wijeyeratne YD, Heptinstall S: Anti-platelet therapy: ADP receptor antagonists. *Br J Clin Pharmacol* 72: 647, 2011. [PMID: 21518389]
57. Alonso-Coello P, Bellmunt S, McGorrian C, et al: Antithrombotic therapy in peripheral arterial disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl): e669S, 2012. [PMID: 22315275]
58. Vandvik PO, Lincoff AM, Gore JM, et al: Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl): e637S, 2012. [PMID: 22315274]
59. Landsberg MG, O'Donnell MJ, Khatri P, et al: Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 (2 Suppl): e601S, 2012. [PMID: 22315273]
60. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP: CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. *JAMA* 306: 2704, 2011. [PMID: 22203539]
61. Ma TK, Lam YY, Tan VR, Yan BP: Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? *Br J Clin Pharmacol* 72: 697, 2011. [PMID: 21352268]
62. Nawarskas JJ, Snowden SS: Critical appraisal of ticagrelor in the management of acute coronary syndrome. *Ther Clin Risk Manag* 7: 473, 2011. [PMID: 22241994]
63. Wallentin L, Becker RC, Budaj A, et al: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 361: 1045, 2009. [PMID: 19717846]
64. Greenhalgh J, Bagust A, Boland A, et al: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. *Health Technol Assess* 15: 1, 2011. [PMID: 21888837]
65. Gresele P, Momi S, Falcinelli E: Anti-platelet therapy: phosphodiesterase inhibitors. *Br J Clin Pharmacol* 72: 634, 2011. [PMID: 21649691]
66. Squires H, Simpson E, Meng Y, et al: A systematic review and economic evaluation of cilostazol, naftidofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. *Health Technol Assess* 15: 1, 2011. [PMID: 22142554]
67. Schneider DJ: Anti-platelet therapy: glycoprotein IIb/IIIa antagonists. *Br J Clin Pharmacol* 72: 672, 2011. [PMID: 21906121]
68. Friedland S, Eisenberg MJ, Shimony A: Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome. *Am J Cardiol* 108: 1244, 2011. [PMID: 22000626]
69. Giugliano RP, White JA, Bode C, et al: Early versus delayed, provisional eptifibatide in acute coronary syndromes. *N Engl J Med* 360: 2176, 2009. [PMID: 19332455]
70. Peacock WF, Hollander JE, Smalling RW, Bresler MJ: Reperfusion strategies in the emergency treatment of ST-segment elevation myocardial infarction. *Am J Emerg Med* 25: 353, 2007. [PMID: 17349914]
71. Boden WE, Eagle K, Granger CB: Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management option. *J Am Coll Cardiol* 50: 917, 2007. [PMID: 17765117]
72. Kunadian V, Gibson CM: Thrombolytics and myocardial infarction. *Cardiovasc Ther* 30: e81, 2012. [PMID: 21070617]
73. Cannon CP: Thrombolysis medication errors: benefits of bolus thrombolytic agents. *Am J Cardiol* 85: 17C, 2000. [PMID: 10793176]
74. Powers WJ, Rabinstein AA, Ackerson T, et al: 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 49:e46, 2018. [PMID: 29367334]
75. Kheiri B, Osman M, Abdalla A, et al: Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. *J Thromb Thrombolysis* 46:440, 2018. [PMID: 30117036]
76. Mehta RH, Alexander JH, Van de Werf F, et al: Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. *JAMA* 293: 1746, 2005. [PMID: 15827313]
77. Landsberg MG, Albers GW, Wijman CA: Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. *Cerebrovasc Dis* 24: 1, 2007. [PMID: 17519538]
78. McCormack PL: Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. *Drugs* 72: 585, 2012. [PMID: 22397329]
79. Tengborn L, Blombäck M, Berntorp E: Tranexamic acid—an old drug still going strong and making a revival. *Thromb Res* 135: 231, 2015. [PMID: 25559460]
80. Coppola A, Windyga J, Tufano A, Yeung C, Di Minno MN: Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. *Cochrane Database Syst Rev* 2015 Feb 9;2:CD009961. [PMID: 25922858]
81. Hunt BJ: The current place of tranexamic acid in the management of bleeding. *Anaesthesia* 70 Suppl 1: e18, 2015. [PMID: 25440395]
82. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, et al: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet* 376(9734): 23, 2010. [PMID: 20554319]
83. CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, et al: The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. *Lancet* 377(9771): 1096, 2011. [PMID: 21439633]
84. Roberts I, Prieto-Merino D, Manno D: Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. *Crit Care* 18: 685, 2014. [PMID: 25498484]
85. Roberts I, Shakur H, Ker K, Coats T; CRASH-2 Trial collaborators. Antifibrinolytic drugs for acute traumatic injury. *Cochrane Database Syst Rev* 2012;12:CD004896. [PMID: 23418644]
86. Pusateri AE, Weiskopf RB, Bebatra V, et al; US DoD Hemorrhage and Resuscitation Research and Development Steering Committee: Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. *Shock* 39: 121, 2013. [PMID: 23222525]
87. Sentilhes L, Lasocki S, Ducloy-Bouthors AS, et al: Tranexamic acid for the prevention and treatment of postpartum haemorrhage. *Br J Anaesth* 114: 576, 2015. [PMID: 25571934]
88. Cross C, Singh M, Jones J: BET 1: Intravenous tranexamic acid for the treatment of post-partum haemorrhage. *Emerg Med J* 35:523, 2018. [PMID: 30030237]
89. Franchini M, Mengoli C, Cruciani M, et al: Safety and efficacy of tranexamic acid for prevention of obstetric haemorrhage: an updated systematic review and meta-analysis. *Blood Transf* 16: 329, 2018. [PMID: 29757132]
90. Prutsky G, Domecq JP, Salazar CA, Accinelli R: Antifibrinolytic therapy to reduce haemoptysis from any cause. *Cochrane Database Syst Rev* 2012 Apr 18;4:CD008711. [PMID: 22513965]
91. Moen CA, Burrell A, Dunning J: Does tranexamic acid stop haemoptysis? *Interact Cardiovasc Thorac Surg* 17: 991, 2013. [PMID: 23966576]
92. Bennett C, Klingenberg SL, Langholz E, Gluud LL: Tranexamic acid for upper gastrointestinal bleeding. *Cochrane Database Syst Rev* 2014 Nov 21;11:CD006640. [PMID: 25414987]
93. Baharoglu MI, Germans MR, Rinkel GJ, Algra A, Vermeulen M, van Gijn J, Roos YB: Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev* 2013 Aug 30;8:CD001245. [PMID: 23990381]
94. Weng S, Wang W, Wei Q, et al: Effect of tranexamic acid in patients with traumatic brain injury: a systematic review and meta-analysis. *World Neurosurg* 123: 128, 2019. [PMID: 30529516]
95. Annichino-Bizzacchi JM, Facchini RM, Torresan MZ, Arruda VR: Hereditary hemorrhagic telangiectasia response to aminocaproic acid treatment. *Thromb Res* 96: 73, 1999. [PMID: 10554087]
96. Longacre AV, Gross CP, Gallitelli M, Henderson KJ, White RI Jr, Proctor DD: Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. *Am J Gastroenterol* 98: 59, 2003. [PMID: 12526937]
97. Gharaibeh A, Savage HI, Scherer RW, Goldberg MF, Lindsley K: Medical interventions for traumatic hyphema. *Cochrane Database Syst Rev* 2013 Dec 3;12:CD005431. [PMID: 24302299]
98. Joseph J, Martinez-Devesa P, Bellorini J, Burton MJ: Tranexamic acid for patients with nasal haemorrhage (epistaxis). *Cochrane Database Syst Rev* 2018 Dec 31;12:CD004328. [PMID: 30596479]
99. Gottlieb M, DeMott JM, Peksa GD: Topical Tranexamic Acid for the Treatment of Acute Epistaxis: A Systematic Review and Meta-analysis. *Ann Pharmacother* 53: 652, 2019. [PMID: 30577703]
100. Ross J, Al-Shahi Salman R: The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials. *Curr Drug Saf* 7: 44, 2012. [PMID: 22663958]